Zoono Group (ASX:ZNO) YoY EBITDA Growth: 83.33% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Zoono Group YoY EBITDA Growth?

Zoono Group ASX:ZNO YoY EBITDA Growth is 83.33% as of Jun. 2026. The stock has 3 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Zoono Group's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 83.33%.

Zoono Group's EBITDA per Share for the six months ended in Jun. 2026 was A$-0.00.

Zoono Group YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Zoono Group's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zoono Group YoY EBITDA Growth Chart

Zoono Group Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -296.30 96.23 -1,750.00 75.68 55.56

Zoono Group Semi-Annual Data
Jun16 Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -28.57 85.71 33.33 0.00 83.33

Zoono Group YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Zoono Group's YoY EBITDA Growth for the fiscal year that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (A: Jun. 2026 )
=(EBITDA per Share (A: Jun. 2026 )-EBITDA per Share (A: Jun. 2025 ))/ | EBITDA per Share (A: Jun. 2025 ) |
=(-0.004--0.009)/ | -0.009 |
=55.56 %

Zoono Group's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(-0.001--0.006)/ | -0.006 |
=83.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 83.33% mean?
Zoono Group (ASX:ZNO) has a YoY EBITDA Growth of 83.33% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Zoono Group and its competitors.
Is Zoono Group's YoY EBITDA Growth too high?
Zoono Group's current YoY EBITDA Growth is 83.33%.
How does Zoono Group's YoY EBITDA Growth compare to PG and CL?
Zoono Group's YoY EBITDA Growth of 83.33% can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Consumer Packaged Goods company?
A good YoY EBITDA Growth depends on the Consumer Packaged Goods industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Zoono Group and its competitors. Zoono Group's current YoY EBITDA Growth is 83.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zoono Group stock overvalued right now?
Based on GuruFocus' analysis, Zoono Group (ASX:ZNO) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.06 — trading 180% above its estimated fair value. The current YoY EBITDA Growth is 83.33%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Zoono Group (ASX:ZNO), the current YoY EBITDA Growth is 83.33% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zoono Group Business Description

Other Exchanges ZOONF:USA
Address 24 Bishop Dunn Place, Unit 3, Flatbush, Auckland, NTL, NZL, 2013
Zoono Group Ltd is engaged in the research, development, and sale of a range of antimicrobial products in multiple countries. The company develops products suited for skin care, surface sanitizers, aerosol-based sprays, as well as acne products, and mold remediation treatments. Geographically, it derives a majority of its revenue from Australasia, Asia, the United States, and India, and also has a presence in the United Kingdom and Europe.